Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | Mexico | Healthcare | Pharmaceuticals | MX$16.27T | 74.3x | 0.73 | MX$18,120 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk | Mexico | Healthcare | Pharmaceuticals | MX$7.89T | 27.5x | 1.28 | MX$1,778 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
J&J | Mexico | Healthcare | Pharmaceuticals | MX$7.58T | 26.5x | -0.45 | MX$3,162 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Mexico | Healthcare | Pharmaceuticals | MX$6.93T | 79.2x | -6.49 | MX$3,977.07 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | Mexico | Healthcare | Pharmaceuticals | MX$5.53T | 29.6x | -1 | MX$6,530.24 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca DRC | Mexico | Healthcare | Pharmaceuticals | MX$4.59T | 31.7x | 1.75 | MX$1,483.90 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck&Co | Mexico | Healthcare | Pharmaceuticals | MX$4.54T | 13x | 0 | MX$1,800.61 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | Mexico | Healthcare | Pharmaceuticals | MX$4.32T | 18x | -1.01 | MX$2,027 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Mexico | Healthcare | Pharmaceuticals | MX$3.25T | 38.8x | -0.98 | MX$6,169 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Mexico | Healthcare | Pharmaceuticals | MX$3T | 18.3x | 0.06 | MX$527.50 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Mexico | Healthcare | Pharmaceuticals | MX$2.77T | 22.8x | 3.37 | MX$1,098 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Mexico | Healthcare | Pharmaceuticals | MX$2.46T | 955.2x | -9.7 | MX$2,008.96 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers Squibb | Mexico | Healthcare | Pharmaceuticals | MX$2.37T | -13x | 0.06 | MX$1,162.50 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
McKesson | Mexico | Healthcare | Pharmaceuticals | MX$1.54T | 27.3x | -21.26 | MX$11,995.68 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | Mexico | Healthcare | Pharmaceuticals | MX$1.51T | 22.9x | -0.47 | MX$724 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer | Mexico | Healthcare | Pharmaceuticals | MX$436.65B | -23.3x | -0.31 | MX$435.01 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Teva DRC | Mexico | Healthcare | Pharmaceuticals | MX$396.11B | -11.7x | 0.06 | MX$346 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols Pref | Mexico | Healthcare | Pharmaceuticals | MX$111.57B | 35.1x | MX$126.63 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Bausch Health | Mexico | Healthcare | Pharmaceuticals | MX$48.79B | -13.2x | -0.16 | MX$151 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genomma Lab Int | Mexico | Healthcare | Pharmaceuticals | MX$26.27B | 16.7x | 0.9 | MX$28.40 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.4% Downside | Upgrade to Pro+ |